April - June 2011

June 29, 2011		Late Breaking Data Presented at the American Diabetes Association 71st Annual Scientific Sessions Evaluate the Safety and Tolerability of TAK-875, Takeda's Investigational Compound for the Treatment of Type 2 Diabetes
June 27, 2011		TAKEDA ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR ADCETRIS™ (BRENTUXIMAB VEDOTIN)
June 24, 2011		Takeda Announces Appointment of New Directors Including New Assignment, Corporate Officers, Management of Takeda Pharmaceuticals North America and Chief Integration Officer
June 24, 2011		Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors, Corporate Officers and Senior Management
June 24, 2011		European Medicines Agency Continues Review of Marketing Authorizations for Products Containing Pioglitazone
June 15, 2011		Hib Vaccine TAK-816 Enters into the Phase III Clinical Trial in Japan
June 15, 2011		Takeda to Start Internship Program for Tsinghua University of China
June 15, 2011		Takeda filed ACTOS® Patent Litigations against Generic Companies in Japan
June 13, 2011		DATA PRESENTATIONS SHOWCASE MILLENNIUM LEADERSHIP IN PROTEIN HOMEOSTASIS AT 16th CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
June 13, 2011		Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting
June 13, 2011		Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting
June 13, 2011		Actions Taken on Actos® and Competact® by French Regulatory Authorities
June 7, 2011		Seattle Genetics and Millennium Present Updated Brentuximab Vedotin (SGN-35) Data at ASCO Annual Meeting
June 7, 2011		Millennium Highlights New Protein Homeostasis Data in Metastatic Melanoma and Other Solid Tumors at American Society of Clinical Oncology
June 7, 2011		Novel Velcade Based Combinations Show High Responses in Heavily Pre-treated Patients with Relapsed or Refractory Multiple Myeloma
June 6, 2011		Launch of SONIAS® LD and SONIAS® HD in Japan
June 3, 2011		Eli Lilly and Takeda Enter into Partnership to Market Evista in 7 Asian Markets and Announce Commencement of Takeda’s Promotion of Evista
May 31, 2011		AFFYMAX AND TAKEDA ANNOUNCE THE SUBMISSION OF A NEW DRUG APPLICATION FOR PEGINESATIDE FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC RENAL FAILURE IN PATIENTS ON DIALYSIS
May 20, 2011		Approval of a Change to the Dosage and Administration of Central Precocious Puberty Medications: Leuplin® for Injection 1.88 and Leuplin® for Injection 3.75
May 19, 2011		Takeda to Acquire Nycomed -Transaction will Transform Takeda's Global Business-
May 13, 2011		Start up of clinical phase III study with Lu AA21004 in Japan
May 11, 2011		Nomination of New Director Candidates and Non-Executive Director Candidates
May 11, 2011		2011-2013 Mid-Range PlanTransformation into a New Takeda
May 10, 2011		Top-line Results of the Pivotal Phase 3 Clinical Trial of TAK-085 in Japan for Treatment of Hypertriglyceridemia
May 10, 2011		PALADIN AND TAKEDA SIGN LICENSING AND DISTRIBUTION AGREEMENT FOR FOMEPIZOLE IN JAPAN
May 9, 2011		TAKEDA VENTURES MAKES STRATEGIC INVESTMENT IN FATE THERAPEUTICS
April 28, 2011		AFFYMAX AND TAKEDA REPORT ADDITIONAL PHASE 3 CLINICAL TRIAL DATA FOR PEGINESATIDE IN DIALYSIS PATIENTS AT THE NATIONAL KIDNEY FOUNDATION SPRING CLINICAL MEETINGS
April 28, 2011		Takeda Announces Establishment of a New Sales and Marketing Company in China
April 27, 2011		Takeda's Support with Alinamin®, the top brand vitamin products, for The 2011 off the Pacific coast of Tohoku Earthquake Relief Efforts
April 26, 2011		MILLENNIUM SUBMITS TWO SUPPLEMENTAL NDAs TO FDA FOR VELCADE
April 25, 2011		Takeda Included in the FTSE4Good Global Index for the Seventh Consecutive Year
April 20, 2011		Takeda's Matching Gift Program for The 2011 off the Pacific coast of Tohoku Earthquake Relief Efforts
April 15, 2011		EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients with Hypertension Updated label reflects new FDA guidance on the association between decreased blood pressure and improved cardiovascular outcomes
April 14, 2011		Anti-Cancer Agent AMG 479 Enters into the Phase III Clinical Trial in Japan
April 13, 2011		Takeda and Samyang Form Research Collaboration in Novel DDS Platform Technology for RNAi Therapeutics
April 11, 2011		HEPTARES AND TAKEDA INITIATE DRUG DISCOVERY COLLABORATION FOCUSED ON GPCR LINKED TO CNS DISORDERS
April 1, 2011		Takeda’s Annual Report 2010 and CSR Data Book 2010 Receive the Environmental Communication Awards Excellence Prize in Environmental Reporting
April 1, 2011		Takeda to Sponsor an English Education TV Program "Hello! Mainichi Kaasan (Mom's Life)"